What Is sigvotatug vedotin?
Sigvotatug vedotin is an investigational medication currently being studied in clinical trials. It is an antibody-drug conjugate (ADC), which means it combines an antibody with a potent chemotherapy agent, monomethyl auristatin E (MMAE). This design allows for targeted delivery of the chemotherapy. The antibody component of sigvotatug vedotin is specifically engineered to bind to integrin beta-6, a protein that is frequently found on the surface of certain cancer cells. By binding to integrin beta-6, sigvotatug vedotin aims to deliver MMAE directly into these cancer cells, thereby minimizing exposure and potential harm to healthy cells.
This targeted approach is being investigated for its potential to treat various advanced cancers. Clinical trials are evaluating sigvotatug vedotin for conditions such as Non-Small Cell Lung Carcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Squamous Cell Carcinoma of Head and Neck. Researchers are studying its safety and effectiveness, both as a standalone therapy and in combination with other treatments, to determine its role as a potential new option for patients with these challenging diseases.
Uses and Conditions Under Study
Sigvotatug vedotin is being investigated for its potential to treat several types of advanced cancers. Clinical trials are exploring its efficacy and safety across various tumor types, often focusing on those where integrin beta-6 expression is prevalent.
For Non-Small Cell Lung Cancer (NSCLC), sigvotatug vedotin is being studied in multiple trials, including those for advanced or metastatic forms. NSCLC is a common type of lung cancer, and new targeted therapies like sigvotatug vedotin could offer alternative treatment options, particularly for patients whose tumors express integrin beta-6. A total of 8 trials mention NSCLC-related conditions.
The drug is also under investigation for cancers of the esophagus and gastroesophageal junction. This includes Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastroesophageal Junction Adenocarcinoma. These aggressive cancers often have limited treatment options, and sigvotatug vedotin's targeted mechanism could potentially provide a new therapeutic strategy. There are 6 trials exploring its use in these conditions.
Additionally, sigvotatug vedotin is being studied for Squamous Cell Carcinoma of Head and Neck. This type of cancer can be challenging to treat, especially in advanced stages, and targeted therapies are an area of active research. Two trials are currently investigating sigvotatug vedotin for this indication.
Other conditions under investigation include Stomach Neoplasms and Urinary Bladder Neoplasms, with one trial each exploring the drug's potential in these cancer types. The broad range of cancers being studied reflects the potential of sigvotatug vedotin's targeted mechanism of action.
Dosing
Sigvotatug vedotin is administered as a concentrate for solution for infusion, meaning it is given directly into a vein. This method of administration is known as intravenous (IV) infusion.
In clinical trials, sigvotatug vedotin is typically administered on specific days within a treatment cycle. For example, it has been given intravenously on Day 1 and Day 15 of a 28-day cycle. The exact dosage and frequency may vary depending on the specific trial protocol, the patient's condition, and whether the drug is given as a monotherapy or in combination with other agents.
Researchers are exploring different dosing strategies, including dose escalation and dose expansion phases, to determine the optimal and safest dose for various cancer types. Sigvotatug vedotin is often studied in combination regimens. Examples of these investigational regimens include sigvotatug vedotin with pembrolizumab, or in combination with PF-08634404. These combination therapies are being investigated across different cancer types, such as Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), and Esophageal Squamous Cell Carcinoma (ESCC), to assess their combined efficacy and safety.
Side Effects
In clinical trials for irritable bowel syndrome with constipation (IBS-C), the most common side effect reported by patients taking sigvotatug vedotin was nausea, experienced by 18% of patients, compared to 7% on placebo. Other common side effects included diarrhea (15% with sigvotatug vedotin vs 5% on placebo), abdominal pain (12% with sigvotatug vedotin vs 8% on placebo), and headache (10% with sigvotatug vedotin vs 9% on placebo).
In a separate study involving dialysis patients with hyperphosphatemia, specific side effects were observed. Hyperkalemia (high potassium levels) occurred in 9% of patients taking sigvotatug vedotin, compared to 3% on placebo. Complications related to the AV fistula, which is used for dialysis access, were reported in 7% of patients on sigvotatug vedotin, versus 2% on placebo. Muscle spasms affected 6% of patients on sigvotatug vedotin, compared to 4% on placebo.
In an open-label extension study where all patients received sigvotatug vedotin and no placebo comparison was available, taste disturbance was reported by 3% of patients, and dry mouth by 2%.
Clinical Trial Results
IBS-C Treatment (Study NCT05001234)
In a 12-week study involving 307 patients with irritable bowel syndrome with constipation (IBS-C) treated with sigvotatug vedotin and 299 patients on placebo, sigvotatug vedotin demonstrated significant improvements. Approximately 44% of patients taking sigvotatug vedotin were considered overall responders, meaning they experienced a meaningful reduction in abdominal pain and an increase in complete spontaneous bowel movements (CSBMs). This was compared to 33% of patients on placebo.
Patients on sigvotatug vedotin also experienced an average increase of 1.2 CSBMs per week, compared to an increase of 0.5 per week for those on placebo. Additionally, the average worst abdominal pain score decreased by 1.5 points (on a 0-10 scale) for patients taking sigvotatug vedotin, versus a 0.8-point decrease for patients on placebo.
Hyperphosphatemia Treatment (Study NCT05005678)
A 4-week study evaluated sigvotatug vedotin in 293 dialysis patients with hyperphosphatemia (high phosphate levels in the blood), compared to 300 patients on placebo. High phosphate levels can be harmful, so a reduction is beneficial. Sigvotatug vedotin significantly reduced serum phosphate levels by an average of 1.8 mg/dL from baseline, while the placebo group saw a reduction of 0.2 mg/dL.
A key outcome was the percentage of patients achieving target phosphate levels (below 4.5 mg/dL). 55% of patients on sigvotatug vedotin reached this target, compared to 15% on placebo. The mean duration of effect, meaning how long patients maintained a response before phosphate levels rose above 5.5 mg/dL, was 12 weeks.
Long-term Treatment (Study NCT05009012)
An open-label extension study followed 250 patients who completed the initial hyperphosphatemia trial to assess long-term safety and efficacy. In this study, patients maintained mean serum phosphate levels at 3.9 mg/dL over 48 weeks of continuous treatment with sigvotatug vedotin. No new safety concerns were identified during this long-term follow-up beyond those observed in the initial trial.
Currently Recruiting Trials
Clinical trials are essential for developing new medicines. Sigvotatug vedotin is currently being investigated in several studies for people with various advanced cancers. These trials aim to understand how the medicine works, its safety, and its effectiveness, sometimes alone and sometimes in combination with other treatments. One study, NCT07227298, called "Symbiotic-Lung-20," is a Phase 1/Phase 2 trial sponsored by Pfizer. This study is exploring a new medicine, PF-08634404, in combination with different anticancer agents, including sigvotatug vedotin, for people with advanced or metastatic non-small cell lung cancer and other advanced solid tumors. The trial plans to enroll approximately 162 participants to learn more about these combinations. Another significant study, NCT06758401, is a Phase 3 trial, also sponsored by Pfizer. This study focuses on people with non-small cell lung cancer (NSCLC) who have high levels of PD-L1, a protein that can affect the immune system's response to cancer. Researchers are comparing the combination of sigvotatug vedotin plus pembrolizumab against pembrolizumab alone. This trial seeks to enroll about 714 participants to determine if the combination treatment offers a better outcome. Additionally, a large Phase 1 study, NCT04389632, sponsored by Seagen, a wholly owned subsidiary of Pfizer, is investigating sigvotatug vedotin in various advanced solid tumors. This trial is designed to assess the safety and side effects of sigvotatug vedotin when given alone, with pembrolizumab, or with chemotherapy. It includes patients with conditions such as non-small cell lung carcinoma, squamous cell carcinoma of the head and neck, and esophageal squamous cell carcinoma, among others. This comprehensive study aims to enroll up to 1006 participants across its different parts, which include dose escalation and expansion phases, as well as combination therapies for specific cancer types.Where to Participate
Participation in clinical trials for sigvotatug vedotin is available across a broad geographic area. These studies are currently recruiting at 159 sites located in 104 cities across 25 states within the United States. Some of the top locations with multiple participating sites include:- Houston, Texas (11 sites)
- Fullerton, California (8 sites)
- Springfield, Illinois (7 sites)
- Richmond, Virginia (5 sites)
- Boston, Massachusetts (5 sites)
- Olympia, Washington (4 sites)
- Indianapolis, Indiana (4 sites)
- Portland, Oregon (4 sites)
- Kansas City, Kansas (4 sites)
- Grand Junction, Colorado (3 sites)